Dizal reported Phase 3 data showing its drug Zegfrovy improved progression‑free survival versus chemotherapy in first‑line non‑small cell lung cancer (NSCLC) patients. The readout positions Zegfrovy as a contender in an important first‑line setting where durable PFS improvements can alter standard‑of‑care sequencing. The release also noted Sanofi activity to expand in China and referenced market dynamics around checkpoint inhibitors such as Opdivo: commercial strategy and regional partnerships will be key to translating the clinical win into uptake. Progression‑free survival (PFS) measures the time patients live without disease worsening and is a common regulatory and payer benchmark in oncology.